GO
Loading...

Enter multiple symbols separated by commas

Medicine

More

  • OPDIVO BENEFIT SIGNIFICANTLY HIGHER IN LUNG CANCER TUMORS WITH HIGH LEVEL OF PD-L1 PROTEIN-STUDY.

  • Chicago May 29- Bristol-Myers Squibb Co's drug, Opdivo, improved survival for patients with the most common form of lung cancer, nearly doubling survival for those with high levels of a specific protein in their tumors compared with chemotherapy, according to clinical trial results presented on Friday. The Bristol drug was approved by U.S. regulators in...

  • BRISTOL'S OPDIVO CUTS DEATH RISK 27 PCT IN ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER-STUDY.

  • BRISTOL-MYERS SQUIBB'S OPDIVO EXTENDS SURVIVAL IN ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER-STUDY.

  • WASHINGTON, May 28- The U.S. Food and Drug Administration on Thursday approved the first drug to treat a rare, progressive lung disease that mainly affects women of childbearing age. The drug, Rapamune, known chemically as sirolimus, is made by Pfizer Inc and is designed to treat lymphangioleiomyomatosis, a disease that causes lung damage and affects only two to...

  • WASHINGTON, May 28- U.S. antitrust regulators have settled a long-running fight with Cephalon, now owned by Teva Pharmaceuticals, over how it resolved a patent infringement lawsuit over the sleep disorder drug Provigil, the Federal Trade Commission said on Thursday. Cephalon had been accused by the FTC of illegally protecting its monopoly on Provigil by...

  • Flaws in gene testing revealed Wednesday, 27 May 2015 | 1:37 PM ET
    Genetic testing

    The first report from a big public-private project to improve genetic testing reveals it is not as rock solid as many people believe.

  • Galena Biopharma rises on cancer therapy study Wednesday, 27 May 2015 | 1:37 PM ET

    NEW YORK— Shares of Galena Biopharma rose Wednesday after the cancer drug developer reported promising data from a clinical study of a second potential cancer vaccine. Galena Biopharma said its drug GALE-301 was well-tolerated and patients' immune systems responded to treatment. Maxim Group analyst Jason McCarthy said GALE-301 is similar to a more...

  • May 27- Drug developer GlobeImmune Inc said its experimental hepatitis B drug did not reduce infection in patients after 24 weeks of treatment in a mid-stage study, sending the company's shares down as much as 60 percent to a record low. GlobeImmune, which is developing the drug with Gilead Sciences Inc, is among several drugmakers looking to tap the demand for...

  • Zogenix says former obesity drug reduced seizures in study Wednesday, 27 May 2015 | 11:54 AM ET

    Zogenix said it plans to start late-stage testing of the drug in the second half of 2015, and it hopes to file for marketing approval in the U.S. and the European Union in late 2016.. Zogenix said research has long shown that it can reduce epileptic seizures, however. It is a component of Vivus Inc.' s anti-obesity drug Qsymia.

  • May 27- GlobeImmune Inc said its experimental hepatitis B drug did not meet the main goal of reducing infection in patients after 24 weeks, in a mid-stage trial. GlobeImmune is developing the drug, GS-4774, with Gilead Sciences Inc.. Companies developing hepatitis B drugs include Arrowhead Research Corp, Canada's Tekmira Pharmaceuticals Corp and Isis...

  • GlobeImmune, Gilead Hep B drug fails in mid-stage study Wednesday, 27 May 2015 | 6:50 AM ET

    May 27- GlobeImmune Inc said its experimental hepatitis B drug did not meet the main goal of reducing infection in patients after 24 weeks, in a mid-stage trial. However, the drug was found to reduce HBsAg, an antigen that indicates the strength of hepatitis B infection, after 48 weeks, the company said on Wednesday. GlobeImmune is developing the drug, GS-4774, with...

  • COPENHAGEN, May 26- Bavarian Nordic is hot property after striking two big vaccine deals but the small Danish company is not for sale, despite a wave of consolidation in the healthcare industry, its chief told Reuters. Boosting the immune system is now a top priority for cancer drug companies such as Bristol-Myers, Merck, Roche and AstraZeneca, fuelling renewed...

  • *OIE warns U.S. bird flu viruses could spread to Mexico. PARIS, May 26- An epidemic of bird flu that has devastated U.S. poultry flocks this year is likely to be under control within four months as the United States steps up measures to contain the virus, the head of the World Organisation for Animal Health said. However, there is a high risk that strains of the virus will...

  • WASHINGTON— Sticky plaque gets the most attention, but now healthy seniors at risk of Alzheimer's are letting scientists peek into their brains to see if another culprit is lurking. Reisa Sperling of Boston's Brigham and Women's Hospital and Harvard Medical School, who is leading the so-called A4 study. The A4 study— it stands for Anti-Amyloid Treatment in...

  • DES MOINES, Iowa— Egg prices reached record levels on Friday after a bird flu outbreak decimated the flock, leading to the death of more than 20 million egg-laying hens over the last month in the top producing state of Iowa. The virus spread appears to have slowed but not stopped. Carton egg prices reached a record Friday of $2.32 a dozen for Midwest large eggs, said...

  • May 21- Biotech firm Bluebird Bio Inc said its experimental gene therapy continued to exhibit a positive effect in an ongoing early-stage study of patients with rare types of blood disorders. The product, LentiGlobin, is being tested in patients with beta-thalassemia major and those with severe sickle cell disease, two hereditary conditions.

  • May 20- U.S. healthcare conglomerate Johnson& Johnson said on Wednesday it expects to submit more than 10 new medicines with annual revenue potential of at least $1 billion each to regulators by 2019, and is testing dozens of new uses for existing medicines. J&J said it would file for approval of daratumumab for the blood cancer multiple myeloma in the United...

  • NEW YORK, May 20- A U.S. group is trying to block patents in five countries for Gilead Sciences Inc's costly hepatitis C drug Sovaldi, in a bid to give almost 60 million afflicted people access to cheaper generic versions. In Argentina, Brazil, China, Russia and Ukraine, challenges have been filed against Gilead's patents or patent applications, the New York- based...

  • Man who caught listeria-related meningitis sues Blue Bell Wednesday, 20 May 2015 | 10:14 AM ET

    AUSTIN, Texas— A man is suing Blue Bell, saying he contracted listeria-related meningitis after eating ice cream produced by the company. David Philip Shockley seeks unspecified damages in the negligence lawsuit filed Tuesday in Austin. The lawsuit says Shockley was hospitalized with respiratory failure and septic shock in October 2013 after eating Blue...